Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.3552W HIGH $1.50
Volume
83.51 K
Value Traded
5.31 M
Short % Float
0.57%
-5.74%Week
-19.11%1 Month
-17.88%3 Month
-49.93%6 Month
-98.13%5 Year
-94.81%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
6.49 M
EPS (TTM)
-1.38
P/E Ratio
-
Ent. Value
6.62 M
Total Shares
15.80 M
Float Shares
9.96 M
Insiders
36.98%
Institutions
2.35%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
EVGN Catalyst Timeline
Dated clinical, regulatory and corporate events for Evogene Ltd.
Past FDA Catalysts and PDUFA Decisions
How EVGN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every EVGN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| BMC128 | advanced solid tumors | Phase 1 | 2026-06-02 | total patients: 11; stable disease patients: 5; partial response patients: 1; patients on study: 2Read More | Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary BiomicaRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| RECANATI LEONDirector | Buy | 460,000 1,343,886 held | $0.64 | 08/11/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in EVGN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SILVERARC CAPITAL MANAGEMENT, LLC | 0.2 % (-60 %) | 945.00 K | 307.97 K | -90% ( -2.77 M) |
EVGN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How EVGN ranks across every disease it competes in
Competitive Position is a premium feature
See how EVGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialEVGN News
EVGN▼ -9.8%today
Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors
Evogene Ltd. has entered a cooperation agreement with Pure Capital Group to resolve disputes and reconstitute its Board of Directors. This agreement aims to provide operational stability and allows Evogene to concentrate on its AI-driven small-molecule discovery efforts. The deal includes the replacement of two board members and a commitment to avoid legal disputes.
Read more →EVGNEvogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance
Evogene Ltd. has received a letter from Nasdaq granting an additional 180 days to meet the minimum bid price compliance requirement. The company must ensure its share price reaches at least $1.00 for ten consecutive business days by March 29, 2027, to avoid delisting. Evogene is focused on regaining compliance and may consider a reverse share split if necessary.
Read more →EVGNEvogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward
Evogene Ltd. has responded to dissident shareholders urging a board overhaul, emphasizing the significant changes made in the past 18 months. The company highlights its successful partnerships, reduced cash burn, and new board members with relevant expertise. Evogene encourages shareholders to support its nominees at the upcoming Annual General Meeting.
Read more →EVGNLeading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees
Evogene Ltd. has received recommendations from leading proxy advisory firms ISS and Glass Lewis to support its slate of director nominees at the upcoming Annual General Meeting. The firms highlighted the board's recent turnover and the relevant experience of the management nominees. The board urges shareholders to disregard the dissident nominees, emphasizing the importance of maintaining strategic momentum.
Read more →EVGNEvogene Reports Second Quarter and First Half 2026 Financial Results
Evogene Ltd. reported its financial results for the second quarter and first half of 2026, highlighting a strategic transformation into an AI-driven computational chemistry company. The company has reduced its workforce and operating expenses while establishing six active drug development collaborations. Despite a decrease in revenues, Evogene anticipates a significant reduction in cash burn and has expanded its virtual chemical space significantly.
Read more →EVGN▼ -7.7%on this newsshared move
Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation
Evogene Ltd. will have Chairman Nir Nimrodi participate in a quarterly results call on August 18, 2026, to discuss the situation with dissident shareholders. He will provide insights into the company's perspective and the implications of these developments. The call aims to address shareholder concerns and ensure transparency regarding the company's operations.
Read more →EVGNEvogene Schedules Second Quarter 2026 Financial Results Release
Evogene Ltd. has announced the release of its financial results for the second quarter of 2026, scheduled for August 18, 2026. Following the release, a conference call will be held at 9:00 AM ET to discuss the results. The company specializes in the generative design of small molecules, aiming to innovate in the pharmaceutical and agricultural sectors.
Read more →EVGNEvogene to Present Its Pharma Division Achievements at the BIO International Convention
Conference to be held in San Diego, CA, USA – June 22-25, 2026 REHOVOT, Israel, June 9, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in AI-based generative design of small molecules for the pharmaceut
Read more →EVGN▼ -13.6%on this news
Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica
Evogene Ltd. announced the successful completion of a Phase 1 clinical study of BMC128, a live bacterial product, in combination with Nivolumab for patients with advanced solid tumors. The study demonstrated a favorable safety profile and preliminary signs of clinical activity, with several patients achieving stable disease. The findings support the continued development of BMC128 by Lishan Biotech.
Read more →EVGNEvogene Reports First Quarter 2026 Financial Results
Conference call and webcast: today, May 20, 2026, 9:00 AM ET REHOVOT, Israel, May 20, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical
Read more →EVGNEvogene to Present at the 24th Schrödinger European User Group Meeting
Conference will be held in Munich, Germany - May 19-21, 2026 REHOVOT, Israel, May 12, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical
Read more →EVGNEvogene Schedules First Quarter 2026 Financial Results Release
Zoom conference call scheduled for May 20, 2026, 9:00 AM ET REHOVOT, Israel, May 7, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and
Read more →EVGNEvogene Reports Receipt of Nasdaq Minimum Bid Price Notification
Evogene Ltd. received a notification from Nasdaq regarding non-compliance with the minimum bid price rule, as its shares have been below $1.00 for 30 consecutive business days. The company has 180 days to regain compliance, with options including a potential reverse stock split. Failure to comply may result in delisting from Nasdaq, although trading will continue during this period.
Read more →EVGNEvogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026
Evogene Ltd. will present its latest pharmaceutical discoveries at the BIO-Europe Spring 2026 conference in Lisbon. Key presentations will focus on the company's advancements in AI-driven small-molecule discovery, particularly through its ChemPass AI™ technology. Attendees will have the opportunity to meet with Evogene's executives for further discussions on collaborative drug discovery.
Read more →EVGN▼ -6.2%on this newsshared move
Evogene Reports Fourth Quarter and Full Year 2025 Financial Results
Evogene Ltd. reported its financial results for Q4 and full year 2025, revealing a strategic shift towards its ChemPass AI™ technology for small-molecule discovery in pharma and agriculture. Despite a decrease in revenues and increased operating losses, the company is optimistic about its future, bolstered by advancements in AI and strategic partnerships. The focus on core activities aims to drive sustainable long-term value.
Read more →EVGNEvogene Releases CEO Letter to Shareholders
Evogene Ltd. has issued a letter from CEO Ofer Haviv detailing the company's strategic transformation in 2025, focusing on its ChemPass AI™ platform for drug discovery and agricultural applications. The company has streamlined operations, divested non-core assets, and established strategic partnerships to enhance its market position. Evogene aims to create sustainable value through innovation in human health and agriculture.
Read more →EVGN▼ -5.6%on this news
Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release
Zoom conference call scheduled for March 5, 2026, 9:00 AM ET REHOVOT, Israel, Feb. 19, 2026 /PRNewswire/ -- Evogene Ltd . (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical
Read more →EVGNEvogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics
Aiming to introduce a new therapeutic strategy for overcoming chemotherapy resistance in lung cancer due to increased expression of cellular pathways REHOVOT, Israel, Feb. 17, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry com
Read more →EVGN▼ -10.2%on this news
Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds
Evogene Ltd. has announced a warrant inducement transaction that will generate approximately $3.4 million in gross proceeds. The company will use the funds for working capital and corporate purposes. The agreement involves the immediate exercise of existing warrants at a reduced price, along with the issuance of new warrants to the investor. The transaction is expected to close on February 11, 2026, pending customary conditions.
Read more →EVGN▼ -7.3%on this newsshared move
Evogene Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI™
Evogene Ltd. has announced an expanded collaboration with Google Cloud to integrate advanced AI agents into its ChemPass AI™ platform. This initiative aims to enhance the efficiency and precision of small-molecule discovery and optimization for pharmaceuticals and agricultural products. The collaboration builds on a previous successful phase and positions Evogene as a leader in next-generation molecular design.
Read more →About Evogene Ltd.
HeadquartersRehovot
Founded1999
BIOPHARMAWATCH ELITE PLUS
Trade the next EVGN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime